PCI Biotech Holding Valuation

Is 0JGL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0JGL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0JGL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0JGL's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0JGL?

Key metric: As 0JGL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0JGL. This is calculated by dividing 0JGL's market cap by their current revenue.
What is 0JGL's PS Ratio?
PS Ratio	9.3x
Sales	NOK 6.00m
Market Cap	NOK 55.99m

0JGL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.3x
Enterprise Value/EBITDA	-1.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 0JGL's PS Ratio compare to its peers?

The above table shows the PS ratio for 0JGL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.7x
APTA Aptamer Group	6.9x	n/a	UK£6.0m
GENF Genflow Biosciences	9.5x	n/a	UK£5.7m
VRCI Verici Dx	2.2x	78.8%	UK£7.6m
PBX ProBiotix Health	4.3x	n/a	UK£9.1m
0JGL PCI Biotech Holding	9.3x	n/a	NOK 56.0m

Price-To-Sales vs Peers: 0JGL is expensive based on its Price-To-Sales Ratio (9.3x) compared to the peer average (5.7x).

Price to Sales Ratio vs Industry

How does 0JGL's PS Ratio compare vs other companies in the GB Biotechs Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
GNS Genus	1.7x	3.5%	US$1.44b
OXB Oxford Biomedica	4.6x	21.2%	US$575.40m
TRX Tissue Regenix Group	1.6x	15.1%	US$52.20m
PBX ProBiotix Health	4.3x	n/a	US$11.59m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 0JGL is expensive based on its Price-To-Sales Ratio (9.3x) compared to the European Biotechs industry average (8.2x).

Price to Sales Ratio vs Fair Ratio

What is 0JGL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0JGL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	9.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0JGL's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Regeneron Pharmaceuticals

US$80.7b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$750.22

0.2%

-7.7%

hVIVO

UK£148.0m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

-1.1%

6.4%

Hikma Pharmaceuticals

UK£4.3b

Develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.

HIKL

UK£19.37

-1.4%

10.0%